Ghulam J Mufti

TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.

Eva Hellström-Lindberg, Brigitte Schlegelberger, Anette Hedlund, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Whole genome scanning as a cytogenetic tool in hematologic malignancies.

G. Mufti, J. Maciejewski, Ghulam J Mufti, 2008, Blood.

Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia.

Eleanor Woodward, G. Mufti, K. Mills, 2005, Biochemical and biophysical research communications.

TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis

G. Mufti, N. Lea, B. Czepulkowski, 2013, British journal of haematology.

Morphological evaluation of monocytes and their precursors

John M Bennett, B. Bain, G. Mufti, 2009, Haematologica.

Cord blood stem cells for hematopoietic stem cell transplantation in the UK: how big should the bank be?

Sergio Querol, G. Mufti, A. Little, 2009, Haematologica.

Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.

G. Mufti, N. Heaton, N. Lea, 2005, Gastroenterology.

Applying synthetic lethality for the selective targeting of cancer.

G. Mufti, D. Mclornan, Ghulam J Mufti, 2014, The New England journal of medicine.

Valuation of transfusion-free living in MDS: results of health utility interviews with patients

Pierre Fenaux, Michael Lübbert, T. Goss, 2009, Health and quality of life outcomes.

Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes

G. Mufti, A. Mohamedali, Ghulam J Mufti, 2013, British journal of haematology.

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Valeria Santini, Robert Schoch, Pierre Fenaux, 2009, The Lancet. Oncology.